CAMBRIDGE AND NEWCASTLE, UK, September 3, 2020 — Atelerix Ltd (Atelerix), pioneers in the storage and transport of cells at room temperature, has received a significant award under the UK Innovation and Science Seed Fund (UKI2S) Accelerator Programme from Innovate UK, the UK’s innovation agency. The funding will support the development of room temperature solutions for shipping therapeutic cells, as part of the company’s “BloodReady” project. This project will explore scalable methods of cell preservation, transport, and re-presentation for patient administration to offer cell therapy developers and manufacturers flexibility in workflows, and remove the need for expedited shipments of frozen packages.
Living cells are fragile and short-lived outside of their natural environment. Therapies that are frozen for storage can reduce the viability and potency of the cells when thawed for injection into the patient, and those that cannot be frozen often require complicated and expensive logistics to ensure their delivery